Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show the superiority of CHF 1535 (BDP/FF) pMDI over BDP HFA
pMDI in terms of lung function considering change from baseline to the entire treatment
period in average pre-dose morning PEF in adult asthmatic patients not adequately controlled
on high doses of ICS or on medium dose of ICS+LABA.